Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 78

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 78
---
 given year. The target annual cash bonuses for 2024 for each of our named executive officers, expressed as a percentage of base salary, were as follows: Mr. Ingram 100%, and Dr. Rodino-Klapac, Messrs. Estepan, Murray, Brown, and Arif 50%. The compensation committee and the Board reviewed and discussed each of our corporate goals and the Company’s achievement towards each goal when determining the scores for each of our primary focus corporate goal areas. The compensation committee also reviewed with the Chief Executive Officer the performance of each named executive officer (excluding the Chief Executive Officer) and his or her contributions towards achieving the 2024 goals.

<div align='center'>52</div>

In 2024, the compensation committee and the Board determined the following with respect to each of our primary focus corporate goal areas:

| Goal Area              | Metric                                                                                                                                                                                                                                                                                | Achievement                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Target | Achievement |
| Elevidys               | Label expansion of Elevidys to all ambulatory patients                                                                                                                                                                                                                                | - Achieved four-year old and older traditional approval- Also achieved non-ambulatory accelerated approval                                                                                                                                                                                                                                                                                                                                                       | 40%    | 60%         |
| 2024 Revenue Goals     | Assuming a full label expansion of Elevidys: $1.31 billion in total Company revenue                                                                                                                                                                                                   | - Greatly exceeded revenue goals, including approximately $821 million in total revenue for Elevidys and approximately $967 million in total revenue for our phosphorodiamidate morpholino oligomer ("PMO") products, resulting in total Company revenue of $1.79 billion                                                                                                                                                                                        | 30%    | 45%         |
| External Opportunities | Continue to search, evaluate and conduct cross-functional diligence on potential significant business development opportunities to deepen our pipeline                                                                                                                                | - Conducted various evaluations of external opportunities- Signed Collaboration and License Agreement with Arrowhead Pharmaceuticals, Inc., resulting in Sarepta obtaining an exclusive worldwide license to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including siRNA-based treatments for DM1 and FSHD                                                                         | 10%    | 13%         |
| Advance Pipeline       | Continue to advance our pipeline and capabilities, including the following activities: - Continue to evaluate SRP-5051 program- Complete enrollment of SRP-9003- Execute on ongoing clinical trials- Continue to advance manufacturing objectives, including suspension manufacturing | - Discontinued SRP-5051